Evidence map›Paper›PMID 18598225›Full record

ReviewExpert review of molecular diagnostics2008

Role of DMP1 and its future in lung cancer diagnostics.

Takayuki Sugiyama, Donna P Frazier, Pankaj Taneja, Rachel L Morgan, Mark C Willingham, Kazushi Inoue

Erratum issuedOpen access · greenAbstract readReview
In one paragraph

Review in Expert review of molecular diagnostics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. c-MYB and DMTF1 in Cancer.Cancer investigation · 2019
    Review
  6. Article
  7. Review
  8. Novel Molecular Markers for Breast Cancer.Biomarkers in cancer · 2016
    Review
  9. Clinical applications of mouse models for breast cancer engaging HER2/neu.Integrative cancer science and therapeutics · 2016
    Article
  10. Article
  11. Article
  12. Aberrant expression of cyclin D1 in cancer.Signal transduction insights · 2015
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Haploinsufficient tumor suppressor genes.Advances in medicine and biology
    Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Takayuki SugiyamaThe Department of Pathology & Cancer Biology, Wake Forest University Health Sciences, Medical Center Boulevard, Winston-Salem, NC 27157-0001, USA. tsugiyam@wfubmc.edu
Donna P Frazier
Pankaj Taneja
Rachel L Morgan
Mark C Willingham
Kazushi Inoue
Wake Forest University · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Training Program in Cancer BiologyT32CA079448 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KRIDEL, STEVEN J. · 2000 to 2014
$6.5M
Roles of DMP1 in Ras signaling and lung cancerR01CA106314 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SUI, GUANGCHAO · 2004 to 2013
$2.6M
NCI NIH HHS 5R01CA106314NCI NIH HHS 5T32CA079448NCI NIH HHS P30 CA012197NCI NIH HHS P30CA12197GACNCI NIH HHS R01 CA106314NCI NIH HHS T32 CA079448
6 · The paper itself

Abstract

Lung cancer is the most lethal carcinoma worldwide. Mutations of p53, inactivation of p16(INK4a), and overexpression of cyclins E, A and B are independently associated with poor prognoses of patients, while the prognostic value of cyclin D1 or RB expression is inconclusive. Cyclin D binding myb-like protein 1 (Dmp1) encodes a DNA binding protein that receives signals from oncogenic Ras and functions as a tumor suppressor by activating the Arf-p53 [corrected] pathway. Dmp1 has been shown to be haplo-insufficient for tumor suppression in mouse models including K-ras-mediated lung carcinogenesis. The human DMP1 gene is located on chromosome 7q21, and our recent results revealed that the hDMP1 gene is deleted, but not mutated or silenced, in approximately 40 % of human non-small-cell lung carcinomas. These cases typically retained wild-type ARF and p53 and expressed very low levels of the hDMP1 protein. Thus, hDMP1 loss could be a novel diagnostic marker for non-small-cell lung carcinomas.

Indexed as

Gene DeletionAnimalsBiomarkers, TumorCarcinoma, Non-Small-Cell LungChromosomes, Human, Pair 7Cyclin-Dependent Kinase Inhibitor p16CyclinsDisease Models, AnimalGene Expression Regulation, NeoplasticHumansLung NeoplasmsMicePrognosisProto-Oncogene Proteins p21(ras)Transcription FactorsTumor Suppressor Protein p53Biomarkers, TumorCyclin-Dependent Kinase Inhibitor p16CyclinsDMTF1 protein, humanDmtf1 protein, mouseProto-Oncogene Proteins p21(ras)TP53 protein, humanTranscription FactorsTumor Suppressor Protein p53

Identifiers

PMID18598225
PMCPMC3749846
OpenAlexW2120704865

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.